MeCP2 attenuates inflammation and regulates T cell phenotype via SFRP4 suppression in preeclampsia
Molecular and Cellular Endocrinology · 2025
DOI: 10.1016/j.mce.2025.112637 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2025. Verfasst von Mei Peng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China. Electronic address:…. Hauptthemen laut MEDLINE: Methyl-CpG-Binding Protein 2, Pre-Eclampsia, Inflammation, Proto-Oncogene Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Central South University.
Abstract (Originalsprache)
Preeclampsia (PE) is a major pregnancy complication characterized by an aberrant immune response. Methyl CpG binding protein 2 (MeCP2) is a potential regulator of secreted frizzled-related protein 4 (SFRP4), and both MeCP2 and SFRP4 are implicated in immune homeostasis. This study investigated the regulatory role of MeCP2/SFRP4 in immune cells in PE. A rat model of PE induced by reduced uterine perfusion pressure (RUPP) and an in vitro model using lipopolysaccharide (LPS)-stimulated HTR-8/SVneo cells were established. A co-culture system of LPS-challenged HTR-8/SVneo cells and T cells was also employed. MeCP2 expression was reduced and inversely correlated with SFRP4 levels in PE. MeCP2 overexpression suppressed Th1/Th17 differentiation while promoting Th2/Treg phenotypes, along with modulation of associated immune cytokines. It also enhanced colony formation, proliferation, migration, and invasion, while reducing apoptosis following co-culture. SFRP4 supplementation reversed the effects of MeCP2 overexpression on T cell proliferation and cytokine release. Collectively, these findings suggest that MeCP2 regulates T cell phenotype and inflammatory responses by inhibiting SFRP4, providing potential avenues for immunotherapeutic intervention in PE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China. Electronic address: pm3971@csu.edu.cn.
- Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Förderung
- Natural Science Foundation of Hunan Province
- Central South University
Zitieren
APA
Peng, M., Nie, Y., Luo, Y., Nkoua, G. D. M., Zhang, S., Liu, H., Zhang, W., Xiao, S., Zhou, Y., Lai, W., Deng, Y., Yu, L., Liu, J., Zhou, X., & Ding, Y. (2025). MeCP2 attenuates inflammation and regulates T cell phenotype via SFRP4 suppression in preeclampsia. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2025.112637
Vancouver
Peng M, Nie Y, Luo Y, Nkoua GDM, Zhang S, Liu H, et al. MeCP2 attenuates inflammation and regulates T cell phenotype via SFRP4 suppression in preeclampsia. Molecular and Cellular Endocrinology. 2025. doi:10.1016/j.mce.2025.112637
BibTeX
@article{Peng2025,
author = {Peng, Mei and Nie, Yanting and Luo, Ying and Nkoua, Grace Divine Milebe and Zhang, Shaohan and Liu, Hongyu and Zhang, Wen and Xiao, Songyuan and Zhou, Yang and Lai, Weisi and Deng, Yali and Yu, Ling and Liu, Jinyu and Zhou, Xihong and Ding, Yiling},
title = {MeCP2 attenuates inflammation and regulates T cell phenotype via SFRP4 suppression in preeclampsia},
journal = {Molecular and Cellular Endocrinology},
year = {2025},
doi = {10.1016/j.mce.2025.112637}
}
EUVIMED